Gusacitinib
As of the edition of 20 October 2026, Gusacitinib is a small molecule: stopped in 2025; acts on JAK1, JAK2 and JAK3 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 10, 2 stopped early
- Disease areas
- Inherited and neonatal; Skin and connective tissue; Cancer; Immune system; Bones, joints and muscles; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
10 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product10 company-target rows are on route A because of Gusacitinib.
See the 10 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 7 | 4 | 0 | 2 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Asana BioSciences | Lead sponsor of trials | 2015 to now |
| Ascend Therapeutics | Lead sponsor of trials | 2015 to now |